AbbVie (ABBV) said Thursday it expects to report Q1 adjusted earnings of $2.34 to $2.38 per diluted share, reflecting an unfavorable impact of $0.13 per share from $248 million in acquired in-process research and development expenses and milestone payments.
Analysts polled by Factset, on average, are expecting $2.51.
The company said it now expects full-year 2025 adjusted earnings of $11.99 to $12.19 per share, down from its prior guidance of $12.12 to $12.32 issued in January.
Analysts are modeling for a $12.30 profit.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。